Medicines360 and Pharma Dynamics have announced the availability of AVIBELA, South Africa’s first generic levonorgestrel 52 mg intrauterine device (IUD), marking a significant step forward in access ...

Rakovina’s AI-powered discovery approach leverages generative AI platforms to evaluate billions of potential drug candidates at a pace not achievable through traditional methods. These capabilities ...

Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US . Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to th ...

Appointment strengthens Elkedonia's governance as the company continues its development and prepares for its next phases of growth Pierre d’Epenoux is former CEO of ImCheck Therapeutics, a ...

New treatment option for rare, life-altering pediatric brain tumors  Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda ® (tovorafenib) ...

Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. Expanded approval includes children aged one year and above with stage 2 T1D to ...

Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in ...

No high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3/4 neutropenia, a known AE associated with lymphodepletion and CAR ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...

HemmePure outlines its feminine balance supplement approach, full ingredient disclosure, and urinary tract wellness positioning for women over 35 seeking daily pH support in 2026 New York, NY, April ...

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...

WOBURN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Curiox Biosystems today announced the signing of a Master Software License Agreement with a major global pharmaceutical organization for the ...